Vida Pharmacal Receives Priority Zoonotic Animal Drug Designation for Innovative Chagas Disease Treatment
Accelerates Review and Time to Market to Save More Lives
- First company to receive a PZAD for treating Chagas disease in dogs
- Expected to reduce approval time by months
- Only the second company to receive PZAD designation
SPRING BRANCH, Texas, – Jan. 22, 2026/ – Vida Pharmacal today announced that its innovative amiodarone + itraconazole drug for treating Chagas disease in dogs has received Priority Zoonotic Animal Drug (PZAD) designation from the U.S. Food & Drug Administration (FDA). Vida is the first company to receive a PZAD designation for Chagas disease treatment.
“Gaining a PZAD designation is extremely advantageous,” said Dr. Roy Madigan, D.V.M. and Founder of Vida Pharmacal. “First, it gives our submission priority review, feedback, and wider visibility within the agency. Second, it significantly shortens the approval process, enabling us to bring the drug to market faster. Faster approval saves more lives—of dogs first and ultimately humans.”
Vida Pharmacal originally filed a submission for amiodarone + itraconazole approval in 2019. The PZAD designation emerged in 2024 as guidance out of the Coronavirus Aid, Relief, and Economic Security (CARES) Act. PZAD designation is reserved for new animal drugs designed to prevent or treat zoonotic diseases in animals that also have the potential to cause adverse health consequences or serious/life-threatening diseases in humans.
Vida Pharmacal’s amiodarone–itraconazole combination acts on multiple parasite pathways simultaneously, producing membrane disruption, metabolic collapse, and organelle damage in Trypanosoma cruzi, the parasite causing Chagas disease. Transcriptomic and ultrastructural data show widespread repression of metabolic pathways, plus targeted activation of stress-response pathways.
Only one other new animal drug has received a PZAD designation. Credelio Quattro-CA1, from Elanco US, received conditional approval after a PZAD designation for treating infestations by New World screwworms (NWS) in dogs. NWS also affects humans and in endemic in Latin America, South America, and parts of the Caribbean.
About Vida Pharmacal
Vida Pharmacal develops, markets, and distributes diagnostics and pharmaceuticals designed to treat emerging and neglected diseases in veterinary and human patients. Founded in 2017, the company has developed the world’s first treatment for Chagas disease in canines. Vida Pharmacal is headquartered in Spring Branch, Texas. For more information, visit https://www.vidapharmacal.com/.